Unlock instant, AI-driven research and patent intelligence for your innovation.

Novel compounds with analgesic effect

a technology of compound and analgesic effect, applied in the field of new compounds with analgesic effect, can solve the problems of poor selectivity of the .delta. receptor, poor pharmacokinetics, and unsuitable systemic administration of naltrindol

Inactive Publication Date: 2001-09-13
ASTRAZENECA CANADA INC
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

With few exceptions, currently available selective opioid .delta. ligands are peptidic in nature and are unsuitable for administration by systemic routes.
These compounds, e.g. naltrindole, suffer from rather poor (i.e., <10-fold) selectivity for the .delta. receptor vs.
Analgesics that have been identified and are existing in the prior art have many disadvantages such as that they suffer from poor pharmacokinetics and are not analgesic when administered by systemic routes.
Also, it has been documented that preferred compounds, described within the prior art, show significant convulsive effects when administered systemically.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel compounds with analgesic effect
  • Novel compounds with analgesic effect
  • Novel compounds with analgesic effect

Examples

Experimental program
Comparison scheme
Effect test

example 2

Preparation of N,N-Diethyl4-(1-naphtyl-piperidin-4-ylidene-methyl)-benzami-de (Compound 7)

[0093] Method as described for Example 1, using compound 4;(226 mg, 71%):

[0094] m.p. 80-85.degree. C. (MeOH-CH.sub.2Cl.sub.2); .nu..sub.max (KBr) cm.sup.-1 3052, 2970, 1628, 1431, 1286; Anal.Calcd.for C.sub.27H.sub.30N.sub.2O . 0.20CH.sub.2Cl.sub.2: C, 78.62; H, 7.37; N, 6.74. Found: C, 78.63; H, 7.07; N, 6.54; .delta..sub.H (400 MHz, CDCl.sub.3) 1.06 (brs, 3H), 1.16 (brs, 3H), 2.00 (m, 2H), 2.53 (m, 2H), 2.64 (brs, NH), 2.77 (m, 2H), 2.97 (m, 2H), 3.20 (brs, 2H), 3.47 (brs, 2H), 7.26 (m, 5H), 7.43 (m, 3H), 7.74 (m, 2H), 8.0 (m, 1H); .delta..sub.C-13 (100 MHz, CDCl.sub.3) .delta.: 12.8, 14.1, 32.6, 33.5, 39.1, 43.2, 47.9, 48.2, 125.5, 125.7, 125.8, 126.1, 127.1, 127.2, 129.1, 131.9, 132.5, 133.8, 135.1, 138.3, 139.8, 142.6, 171.1.

example 3

Preparation of N,N-Diethyl-4-(2,6-dimethylphenyl-piperidin-4-ylidene-methy-l)-benzamide (Compound 8)

[0095] Method as described for Example 1, using compound 5 (242 mg, 80%).

[0096] Its HCl salt: Dec..gtoreq.115.degree. C. (AcOEt-Ether-CH.sub.2Cl.su-b.2); .nu..sub.max (KBr) cm.sup.-1 2970, 2725, 1590, 1464, 1290, 1101; Anal.Calcd.for C.sub.25H.sub.32N.sub.2O. 1.0 HCl. 0.50CH.sub.2Cl.sub.2. 0.5H.sub.2O: C, 65.94; H, 7.60; N, 6.03. Found: C, 65.98; H, 7.37; N, 5.81.

example 4

Preparation of N,N-Diethyl-4-(1-naphtyl-N-allyl-piperidin-4-ylidene-methyl-)-benzamide (Compound 9)

[0097] A mixture of (.alpha.-(1-Naphthyl)-.alpha.-(4-N',N'-diethylaminocar-bonylphenyl))-4-methylene-piperidine (compound 7) (125 mg), allyl bromide (90 mg) and K.sub.2CO.sub.3 (138 mg) in MeCN (10 mL) was stirred for 14 hr at r.t., and then quenched with 1 N NH.sub.4OH solution, extracted with AcOEt (100 ml). The organic phase was washed with aqueous NH.sub.4Cl solution and brine, dried over MgSO.sub.4. Removal of solvents gave a crude product, which was purified by silica gel column eluting with MeOH-CH.sub.2Cl.sub.2 (2:98) to provide (.alpha.-(1-naphthyl)-.alpha.-(4--N',N'-diethylaminocarbonylphenyl))-4-methylene-N-allylpiperidine (50 mg, 36%):

[0098] .delta..sub.H (400 MHz, CDCl.sub.3) 1.08 (brs, 3H), 1.19 (brs, 3H), 2.08 (m, 2H), 2.39 (m, 2H), 2.61 (m, 4H), 3.01 (m, 2H), 3.24 (brs, 2H), 3.52 (brs, 2H), 5.13 (m, 2H), 5.90 (m, 1H), 7.27 (m, 5H), 7.45 (m, 3H), 7.80 (m, 2H), 8.04 (m, 1...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
Login to View More

Abstract

Compounds of general formula (I) are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.

Description

[0001] The present invention is related to novel compounds, to a process for their preparation, their use and pharmaceutical compositions comprising the novel compounds. The novel compounds are useful in therapy, and in particular for the treatment of pain.BACKGROUND AND PRIOR ART[0002] The .delta. receptor has been identified as having a role in many bodily functions such as circulatory and pain systems. Ligands for the .delta. receptor may therefore find potential use as analgesics, and / or as antihypertensive agents. Ligands for the .delta. receptor have also been shown to possess immunomodulatory activities.[0003] The identification of at least three different populations of opioid receptors (.mu., .delta. and .kappa.) is now well established and all three are apparent in both central and peripheral nervous systems of many species including man. Analgesia has been observed in various animal models when one or more of these receptors has been activated.[0004] With few exceptions, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/4409A61K31/4427A61K31/443A61K31/4436A61K31/445A61K31/4523A61K31/4709A61K31/661A61P25/04A61P29/00C07DC07D211/22C07D211/46C07D211/70C07D213/00C07D307/00C07D307/81C07D333/00C07D401/06C07D405/06C07D409/06C07F9/59
CPCC07D211/46C07D211/70C07D401/06C07D405/06A61P1/04A61P19/08A61P25/00A61P25/04A61P29/00C07D333/20C07D307/80C07D409/06
Inventor DELORME, DANIELROBERTS, EDWARDWEI, ZHONGYONG
Owner ASTRAZENECA CANADA INC